{
    "root": "b6cdef35-e0dc-4de7-86ed-501ee27b4dc3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "doxycycline hyclate"
    },
    "value": "20250415",
    "ingredients": [
        {
            "name": "DOXYCYCLINE HYCLATE",
            "code": "19XTS3T51U"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "reduce development drug-resistant bacteria maintain effectiveness doxycycline hyclate capsules , usp antibacterial drugs , doxycycline hyclate capsules , usp used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy . treatment : doxycycline indicated treatment following infections : rocky mountain spotted fever , typhus fever typhus group , q fever , rickettsialpox , tick fevers caused rickettsiae . respiratory tract infections caused mycoplasma pneumoniae . lymphogranuloma venereum caused chlamydia trachomatis . psittacosis ( ornithosis ) caused chlamydophila psittaci . trachoma caused chlamydia trachomatis , although infectious agent always eliminated , judged immunofluorescence . inclusion conjunctivitis caused chlamydia trachomatis . uncomplicated urethral , endocervical , rectal infections adults caused chlamydia trachomatis . nongonococcal urethritis caused ureaplasma urealyticum . relapsing fever due borrelia recurrentis . doxycycline also indicated treatment infections caused following gram-negative microorganisms : chancroid caused haemophilus ducreyi . plague due yersinia pestis . tularemia due francisella tularensis . cholera caused vibrio cholerae . campylobacter fetus infections caused campylobacter fetus . brucellosis due brucella species ( conjunction streptomycin ) . bartonellosis due bartonella bacilliformis . granuloma inguinale caused klebsiella granulomatis . many strains following groups microorganisms shown resistant doxycycline , culture susceptibility testing recommended . doxycycline indicated treatment infections caused following gram-negative bacteria , bacteriologic testing indicates appropriate susceptibility : escherichia coli . enterobacter aerogenes . shigella species . acinetobacter species . respiratory tract infections caused haemophilus influenzae . respiratory tract urinary tract infections caused klebsiella species . doxycycline indicated treatment infections caused following gram-positive microorganisms bacteriologic testing indicates appropriate susceptibility : upper respiratory infections caused streptococcus pneumoniae . anthrax due bacillus anthracis , including inhalational anthrax ( post-exposure ) : reduce incidence progression disease following exposure aerosolized bacillus anthracis . penicillin contraindicated , doxycycline alternative treatment following infections : uncomplicated gonorrhea caused neisseria gonorrhoeae . syphilis caused treponema pallidum . yaws caused treponema pallidum subspecies pertenue . listeriosis due listeria monocytogenes . vincent ’ infection caused fusobacterium fusiforme . actinomycosis caused actinomyces israelii . infections caused clostridium species . acute intestinal amebiasis , doxycycline may useful adjunct amebicides . severe acne , doxycycline may useful adjunctive therapy . prophylaxis : doxycycline indicated prophylaxis malaria due plasmodium falciparum short-term travelers ( < 4 months ) areas chloroquine and/or pyrimethamine-sulfadoxine resistant strains . ( section information patients subsection section . )",
    "contraindications": "usual frequency doxycycline differs tetracyclines . exceeding recommended may result increased incidence side effects . adults : usual dose oral doxycycline 200 mg first day treatment ( administered 100 mg every 12 hours ) followed maintenance dose 100 mg/day . management severe infections ( particularly chronic infections urinary tract ) , 100 mg every 12 hours recommended . pediatric patients : pediatric patients weighing less 45 kg severe life-threatening infections ( e.g . , anthrax , rocky mountain spotted fever ) , recommended 2.2 mg/kg body weight administered every 12 hours . children weighing 45 kg receive adult dose . ( . ) pediatric patients less severe disease ( greater 8 years age weighing less 45 kg ) , recommended schedule 4.4 mg/kg body weight divided two doses first day treatment , followed maintenance dose 2.2 mg/kg body weight ( given single daily dose divided twice daily doses ) . pediatric patients weighing 45 kg , usual adult dose used . therapeutic antibacterial serum activity usually persist 24 hours following recommended . used streptococcal infections , therapy continued 10 days . adequate amounts fluid along capsule tablet forms drugs tetracycline class recommended wash drugs reduce risk esophageal irritation ulceration . ( . ) gastric irritation occurs , recommended doxycycline given food milk . absorption doxycycline markedly influenced simultaneous ingestion food milk . date indicated doxycycline usual recommended doses lead excessive accumulation doxycycline patients renal impairment . uncomplicated gonococcal infections adults ( except anorectal infections men ) : 100 mg , mouth , twice day 7 days . alternate single visit dose , administer 300 mg stat followed one hour second 300 mg dose . dose may administered food , including milk carbonated beverage , required . uncomplicated urethral , endocervical , rectal infection adults caused chlamydia trachomatis : 100 mg , mouth , twice day 7 days . nongonococcal urethritis ( ngu ) caused c. trachomatis u. urealyticum : 100 mg mouth , twice day 7 days . syphilis – early : patients allergic penicillin treated doxycycline 100 mg , mouth , twice day 2 weeks . syphilis one year ’ duration : patients allergic penicillin treated doxycycline 100 mg , mouth , twice day 4 weeks . acute epididymo-orchitis caused n. gonorrhoeae : 100 mg , mouth , twice day least 10 days . acute epididymo-orchitis caused c. trachomatis : 100 mg , mouth , twice day least 10 days . prophylaxis malaria : adults , recommended dose 100 mg daily . children 8 years age , recommended dose 2 mg/kg given daily adult dose . prophylaxis begin 1 2 days travel malarious area . prophylaxis continued daily travel malarious area 4 weeks traveler leaves malarious area . inhalational anthrax ( post-exposure ) : adults : 100 mg doxycycline , mouth , twice day 60 days . children : weighing less 45 kg ; 2.2 mg/kg body weight , mouth , twice day 60 days . children weighing 45 kg receive adult dose .",
    "warningsAndPrecautions": "doxycycline hyclate capsules usp , 50 mg light blue opaque cap/white opaque body , hard gelatin capsules size “ 2 ” imprinting “ a248 ” cap black ink , filled yellow powder . capsule contains doxycycline hyclate usp equivalent 50 mg doxycycline . ndc 62332-362-50 bottle 50 capsules ndc 62332-362-71 bottle 500 capsules doxycycline hyclate capsules usp , 100 mg light blue opaque cap/light blue opaque body , hard gelatin capsules size “ 0 ” imprinting “ a249 ” cap black ink , filled yellow powder . capsule contains doxycycline hyclate usp equivalent 100 mg doxycycline . ndc 62332-363-50 bottle 50 capsules ndc 62332-363-71 bottle 500 capsules store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense tight , light-resistant containers ( usp ) .",
    "adverseReactions": "contraindicated persons shown hypersensitivity tetracyclines .",
    "indications_original": "To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules, USP and other antibacterial drugs, doxycycline hyclate capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.\n                  \n                     Treatment: \n                  \n                  Doxycycline is indicated for the treatment of the following infections:\n                  \n                     Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.\n                     Respiratory tract infections caused by Mycoplasma pneumoniae. \n                     Lymphogranuloma venereum caused by Chlamydia trachomatis. \n                     Psittacosis (ornithosis) caused by Chlamydophila psittaci.\n                     Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence.\n                     Inclusion conjunctivitis caused by Chlamydia trachomatis.\n                     Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis.\n                     Nongonococcal urethritis caused by Ureaplasma urealyticum. \n                     Relapsing fever due to Borrelia  recurrentis.\n                  \n                  Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:\n                  \n                     Chancroid caused by Haemophilus ducreyi. \n                     Plague due to Yersinia pestis.\n                     Tularemia due to Francisella tularensis. \n                     Cholera caused by Vibrio cholerae.\n                     Campylobacter fetus infections caused by Campylobacter fetus. \n                     Brucellosis due to Brucella species (in conjunction with streptomycin). \n                     Bartonellosis due to Bartonella bacilliformis.\n                     Granuloma inguinale caused by Klebsiella granulomatis.\n                  \n                  Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.\n                  Doxycycline is indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug:\n                  \n                     \n                        Escherichia coli. \n                     \n                        Enterobacter aerogenes. \n                     \n                        Shigella species.\n                     \n                        Acinetobacter species.\n                     Respiratory tract infections caused by Haemophilus influenzae. \n                     Respiratory tract and urinary tract infections caused by Klebsiella species.\n                  \n                  Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:\n                  \n                     Upper respiratory infections caused by Streptococcus pneumoniae.\n                     Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.\n                  \n                  When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:\n                  \n                     Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. \n                     Syphilis caused by Treponema pallidum.\n                     Yaws caused by Treponema pallidum subspecies pertenue. \n                     Listeriosis due to Listeria monocytogenes.\n                     Vincent’s infection caused by Fusobacterium fusiforme. \n                     Actinomycosis caused by Actinomyces israelii.\n                     Infections caused by Clostridium species.\n                  \n                  In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. \n                  In severe acne, doxycycline may be useful adjunctive therapy.\n                     Prophylaxis:\n                  \n                  Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. (See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.)",
    "contraindications_original": "The usual dosage and frequency of administration of doxycycline differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.\n                  \n                  \n                     Adults:\n                  \n                  The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.\n                  \n                  \n                     Pediatric Patients:\n                  \n                  For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage is 2.2 mg/kg of body weight administered every 12 hours. Children weighing 45 kg or more should receive the adult dose. (See WARNINGS and PRECAUTIONS.)\n                  \n                  For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used. \n                  \n                  The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.\n                  \n                  When used in streptococcal infections, therapy should be continued for 10   days.\n                  \n                  Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.)\n                  \n                  If gastric irritation occurs, it is recommended that doxycycline be given with food or milk. The absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk.\n                  \n                  Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of doxycycline in patients with renal impairment.\n                  \n                  Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose. The dose may be administered with food, including milk or carbonated beverage, as required.\n                  \n                  Uncomplicated urethral, endocervical, or rectal infection in adults caused by Chlamydia trachomatis: 100 mg, by mouth, twice a day for 7 days.\n                  \n                  Nongonococcal urethritis (NGU) caused by C. trachomatis or U. urealyticum: 100 mg by mouth, twice a day for 7 days.\n                  \n                  Syphilis – early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 2 weeks.\n                  \n                  Syphilis of more than one year’s duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.\n                  \n                  Acute epididymo-orchitis caused by N. gonorrhoeae: 100 mg, by mouth, twice a day for at least 10 days. \n                  \n                  Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice a day for at least 10 days.\n                  \n                  For prophylaxis of malaria: For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1 to 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.\n                  \n                  Inhalational anthrax (post-exposure):\n                  ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days.\n                  CHILDREN: weighing less than 45 kg; 2.2 mg/kg of body weight, by mouth, twice a day for 60 days. Children weighing 45 kg or more should receive the adult dose.",
    "warningsAndPrecautions_original": "Doxycycline hyclate capsules USP, 50 mg are light blue opaque cap/white opaque body, hard gelatin capsules of size “2” having imprinting “A248” on cap in black ink, filled with yellow powder. Each capsule contains doxycycline hyclate USP equivalent to 50 mg doxycycline.\n                  \n                  NDC 62332-362-50                Bottle of 50 capsules\n                  NDC 62332-362-71                Bottle of 500 capsules\n                  \n                  Doxycycline hyclate capsules USP, 100 mg are light blue opaque cap/light blue opaque body, hard gelatin capsules of size “0” having imprinting “A249” on cap in black ink, filled with yellow powder. Each capsule contains doxycycline hyclate USP equivalent to 100 mg doxycycline.\n                  \n                  NDC 62332-363-50                Bottle of 50 capsules\n                  NDC 62332-363-71                Bottle of 500 capsules\n                   Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in tight, light-resistant containers (USP).",
    "adverseReactions_original": "This drug is contraindicated in persons who have shown hypersensitivity to any of the   tetracyclines."
}